GlassScriptPhysician profile
Evgenia Raichlin
NPI 1700907540
$72,542.59
in general payments reported to CMS, 2019-2025
15 companies · $24K in 2025
The $24K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $6,101 · 2021: $3,749 · 2022: $7,347 · 2023: $622 · 2024: $6,375 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Consulting Fee: $5,750 · Food and Beverage: $1,579 · Travel and Lodging: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,700.00 |
| Consulting Fee | $5,750.00 |
| Food and Beverage | $1,578.68 |
| Travel and Lodging | $570.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $23,350.99 | 2019-2020 | |
| Pfizer INC. | $20,074.69 | 2019-2025 | |
| Bridgebio Pharma, INC. | $17,730.46 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $9,986.50 | 2019-2025 | Onpattro, Amvuttra |
| Abbott Laboratories | $756.09 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Abiomed | $191.45 | 2022-2025 | Impella |
| Cvrx, INC. | $112.66 | 2023 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $95.08 | 2023-2024 | |
| Medtronic, INC. | $85.15 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.41 | 2022-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $34.90 | 2022-2024 | Verquvo |
| Novo Nordisk INC | $21.08 | 2024 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $19.94 | 2024 | |
| Medtronic Vascular, INC. | $15.88 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evgenia Raichlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.